Edition:
United Kingdom

Novartis AG (NOVN.S)

NOVN.S on Virt-X Level 1

80.82CHF
11:34am BST
Change (% chg)

CHF-0.04 (-0.05%)
Prev Close
CHF80.86
Open
CHF81.36
Day's High
CHF81.46
Day's Low
CHF80.82
Volume
1,067,566
Avg. Vol
4,658,644
52-wk High
CHF88.30
52-wk Low
CHF71.84

Chart for

About

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines... (more)

Overall

Beta: 1.05
Market Cap(Mil.): CHF219,900.80
Shares Outstanding(Mil.): 2,616.84
Dividend: 2.75
Yield (%): 3.27

Financials

  NOVN.S Industry Sector
P/E (TTM): 31.37 30.93 32.76
EPS (TTM): 2.68 -- --
ROI: 6.14 15.07 14.61
ROE: 9.19 16.59 16.33

Bank DNB switches US, Europe mutual funds to index tracking

OSLO, Aug 14 Norwegian bank DNB will switch its mutual funds for U.S. and European stocks to index tracking from active management on Aug. 16, it said on Tuesday.

14 Aug 2018

Novartis recruits new compliance head from Siemens after ethics stumbles

ZURICH Novartis has recruited a new chief ethics officer from Siemens after costly bribery scandals and a disputed $1.2 million (938,673.3 pounds) contract with President Donald Trump's former lawyer that the Swiss drugmaker now calls a mistake.

14 Aug 2018

Novartis recruits new compliance head from Siemens after ethics stumbles

ZURICH Novartis has recruited a new chief ethics officer from Siemens after costly bribery scandals and a disputed $1.2 million contract with President Donald Trump's former lawyer that the Swiss drugmaker now calls a mistake.

14 Aug 2018

Novartis recruits new compliance head from Siemens after ethics stumbles

* Novartis hires Siemens lawyer to lead anti-corruption efforts

14 Aug 2018

BRIEF-Novartis appoints Klaus Moosmayer as Chief Ethics Risk and Compliance Officer

* SAYS NOVARTIS APPOINTS DR. KLAUS MOOSMAYER AS CHIEF ETHICS RISK AND COMPLIANCE OFFICER Further company coverage: (Reporting By Zurich newsroom)

14 Aug 2018

BRIEF-Novartis Announces U.S. Renewables Agreement To Reduce Greenhouse Gas Emissions

* NOVARTIS ANNOUNCES US RENEWABLES AGREEMENT TO REDUCE GREENHOUSE GAS EMISSIONS

02 Aug 2018

More drugmakers build Brexit stockpiles as EU agency faces exodus

PARIS/ZURICH/LONDON Sanofi and Novartis said on Wednesday they planned to increase stockpiles of medicines in Britain in preparation for potential disruption if the UK crashes out of the European Union without a deal. | Video

01 Aug 2018

More drugmakers build Brexit stockpiles as EU agency faces exodus

PARIS/ZURICH/LONDON Sanofi and Novartis said on Wednesday they planned to increase stockpiles of medicines in Britain in preparation for potential disruption if the UK crashes out of the European Union without a deal.

01 Aug 2018

UPDATE 3-More drugmakers build Brexit stockpiles as EU agency faces exodus

* Sanofi and Novartis action follows similar move by AstraZeneca

01 Aug 2018

BRIEF-MerLion Regains North American Rights to XTORO

* MERLION PHARMACEUTICALS- NOVARTIS HAS MADE A PORTFOLIO DECISION AND TERMINATED LICENSE BETWEEN ALCON AND MERLION EXECUTED IN 2010

31 Jul 2018

Earnings vs. Estimates